BOBULSKY SUSAN 4
4 · Adaptive Biotechnologies Corp · Filed Mar 6, 2024
Insider Transaction Report
Form 4
BOBULSKY SUSAN
Chief Commercial Officer, MRD
Transactions
- Award
Common Stock
2024-03-04+132,979→ 261,281 total - Award
Stock Option (right to buy)
2024-03-04+199,549→ 199,549 totalExercise: $3.99Exp: 2034-03-04→ Common Stock (199,549 underlying) - Sale
Common Stock
2024-03-05$3.44/sh−6,975$23,994→ 248,290 total - Sale
Common Stock
2024-03-05$3.43/sh−6,016$20,635→ 255,265 total
Footnotes (2)
- [F1]This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
- [F2]The options vest with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.